Zhejiang Orient Gene BiotechLtd Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Xiaoliang Fang

Chief executive officer

CN¥1.2m

Total compensation

CEO salary percentage	n/a
CEO tenure	7.1yrs
CEO ownership	17.4%
Management average tenure	no data
Board average tenure	7.1yrs

Recent management updates

Recent updates

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Apr 30

CEO

Xiaoliang Fang (66 yo)

7.1yrs

Tenure

CN¥1,152,900

Compensation

Mr. Xiaoliang Fang is GM & Director of Zhejiang Orient Gene Biotech Co., Ltd. from April 18, 2017.

Board Members

Name	Position	Tenure	Compensation	Ownership
Xiaoliang Fang	GM & Director	7.1yrs	CN¥1.15m	17.38% CN¥ 1.1b
Xiaoping Han	Independent Director	7.1yrs	CN¥100.00k	no data
Jianqiu Fang	Chairman	7.1yrs	CN¥1.25m	16.41% CN¥ 997.9m
Wei Lin	Independent Director	7.1yrs	CN¥100.00k	no data
Haiying Feng	Chairman of the Board of Supervisors	7.1yrs	no data	0.075% CN¥ 4.6m

7.1yrs

Average Tenure

58yo

Average Age

Experienced Board: 688298's board of directors are considered experienced (7.1 years average tenure).

Zhejiang Orient Gene BiotechLtd Management

Management criteria checks 2/4

Key information

Recent management updates

Zhejiang Orient Gene Biotech Co.,Ltd, Annual General Meeting, May 22, 2024

Recent updates

New major risk - Revenue and earnings growth

Zhejiang Orient Gene Biotech Co.,Ltd, Annual General Meeting, May 22, 2024

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Full year 2023 earnings released: CN¥1.97 loss per share (vs CN¥10.26 profit in FY 2022)

Now 21% undervalued after recent price drop

Zhejiang Orient Gene Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥1.85 loss per share (vs CN¥10.26 profit in FY 2022)

Zhejiang Orient Gene Biotech Co.,Ltd (SHSE:688298) announces an Equity Buyback for CNY 100 million worth of its shares.

Now 21% undervalued after recent price drop

Third quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥1.54 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥3.35 in 2Q 2022)

Zhejiang Orient Gene Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Upcoming dividend of CN¥2.00 per share at 4.0% yield

First quarter 2023 earnings released: CN¥0.30 loss per share (vs CN¥12.30 profit in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥17.74 (vs CN¥29.29 in FY 2021)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥1.84 (vs CN¥3.12 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥4.02 (vs CN¥13.14 in 2Q 2021)

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 33% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Now 23% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥4.37 (vs CN¥1.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥18.40 (vs CN¥3.96 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥9.89 (vs CN¥0.37 in 1Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥14.07 (vs CN¥0.91 in FY 2019)

New 90-day low: CN¥135

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

New 90-day high: CN¥203

Investor sentiment improved over the past week

New 90-day high: CN¥177

Market bids up stock over the past week

Softlab9 Technologies Inc. Purchases Rapid Antigen COVID Testing Kits from Zhejiang Orient Gene Biotech Co. Ltd

New 90-day low - CN¥123

New 90-day high - CN¥260

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age